At the White House today, President Biden signed the American Rescue Plan, a $1.9 trillion COVID-19 relief bill.
At the White House today, President Biden signed the American Rescue Plan, a $1.9 trillion COVID-19 relief bill.
Tyler Huff passed for two touchdowns, ran for another and Rod Haygood's interception with 1:22 remaining sealed Presbyterian's 29-24 win over Davidson on Saturday, avenging an earlier loss to the Wildcats in March. Davidson (4-2, 3-1 Pioneer Football League) rode into into its final game of the spring on four straight wins, including one last week that snapped 25th-ranked San Diego's 39-game PFL win streak. The Wildcats scored first Saturday when Coy Williams ran for the first of his two touchdowns to cap a grinder of a game-opening drive, taking 11 plays to cover 74 yards in 5:32.
– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models – – CFT7455 Promotes Sustained Degradation of IKZF1/3 and Durable Anti-tumor Response, Including Regressions in an IMiD-Insensitive Myeloma Tumor Xenograft Model – – CFT7455 Phase 1/2 Trial in Multiple Myeloma and Non-Hodgkin Lymphomas On Track for 1H 2021 Initiation – WATERTOWN, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today presented preclinical data for CFT7455, the Company’s lead program, a MonoDACTM degrader targeting IKZF1/3 for the treatment of hematologic malignancies. These results, which support clinical evaluation of CFT7455 in multiple myeloma, were delivered as a late-breaking oral presentation during the first session of the American Association for Cancer Research (AACR) Annual Meeting 2021. “IKZF1/3 proteins are critical dependencies of B cell malignancies including multiple myeloma and subsets of non-Hodgkin’s lymphoma,” said Stewart Fisher, Ph.D., chief scientific officer of C4 Therapeutics. “We are pleased to share preclinical data demonstrating that potent catalytic IKZF1/3 degradation activity of CFT7455, coupled with optimized pharmacological properties, can result in regression of multiple myeloma xenograft tumors not responsive to approved IMiD therapies. We are optimistic that the in vitro and in vivo data we saw preclinically will translate into improved, clinically meaningful outcomes for patients and we look forward to initiating our CFT7455 Phase 1/2 clinical trial in the first half of this year.” Summary of Results C4T conducted in vitro studies to confirm CFT7455’s intended mechanism. Notable observations include: CFT7455 binds with high affinity to the E3 ligase adapter protein, cereblon (Kd = 0.9 nM);In vitro, CFT7455 treatment results in deep, rapid degradation of IKZF1/3 proteins, resulting in apoptotic cell death; andCFT7455 demonstrated broad, potent anti-proliferative activity in a panel of multiple myeloma cell lines. In mouse xenograft models of IMiD-insensitive multiple myeloma, data further established CFT7455 as a highly potent, catalytic degrader of IKZF1/3, capable of generating anti-tumor activity as a single agent and in combination with dexamethasone. Notable observations include: In the H929 myeloma xenograft tumor model, daily oral administration of CFT7455 at 0.1 mg/kg for three weeks led to partial or complete tumor regression, with the latter being durable even after stopping treatment.CFT7455 produced deep and durable degradation of IKZF3 in the RPMI-8226 myeloma xenograft tumor model, which is relatively insensitive to pomalidomide. Tumor regression resulted from treatment with CFT7455 in both naïve RPMI-8226 tumors, as well as those previously exposed, but unresponsive, to pomalidomide.The combination of CFT7455 and dexamethasone in the RPMI-8226 tumor xenograft model yielded expected improvements in efficacy and survival outcomes in mice bearing RPMI-8226 xenograft tumors, compared to either agent used alone. Based in part on these results, C4T plans to explore the therapeutic applications of CFT7455 for the treatment of relapsed or refractory multiple myeloma and non-Hodgkin’s lymphomas and expects to initiate a Phase 1/2 clinical study of CFT7455 in the first half of 2021. C4T’s AACR Annual Meeting 2021 presentation will be archived on the “Scientific Publications” page in the Investors section of the Company’s website, located at www.c4therapeutics.com. About CFT7455CFT7455 is an orally bioavailable MonoDAC™ (Monofunctional Degradation Activating Compound) degrader designed to bind with high affinity to the E3 ligase adapter protein, cereblon, to target and degrade IKZF1/3 for the treatment of hematologic malignancies such as multiple myeloma and non-Hodgkin’s lymphoma, including peripheral T cell lymphoma and mantle cell lymphoma. In preclinical studies, CFT7455 has demonstrated potent and selective protein degradation with favorable pharmacological properties. About C4 TherapeuticsC4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com. Forward-Looking StatementsThis press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy or safety profile of our therapeutic approaches; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for regulatory authorization related to clinical trials; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our current resources and cash runway; and regulatory developments in the United States and foreign countries. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing and conduct of preclinical and clinical studies and other development requirements for our product candidates and the risk that the results of preclinical studies and/or clinical trials will or will not be predictive of future results in connection with future studies or trials. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law. CONTACT: Investor & Media Contact Kendra Adams SVP, Communications & Investor Relations Kendra.Adams@c4therapeutics.com
Vanderbilt guard Scotty Pippen Jr. has declared for the NBA draft without signing with an agent to keep his options open. Pippen announced his intentions Saturday morning with a social media post. “We all have dreams and I am ready to pursue mine," Pippen said.
Depleted Bayern Munich were held to a 1-1 draw at home by Union Berlin in the Bundesliga on Saturday, three days before their Champions League return leg at Paris Saint-Germain.
Apr. 10—NORWALK — For the past almost 20 years, Malcolm Pearce has been serving up customer service at Schild's IGA as a grocery bagger. On Friday he was serving up cupcakes on his final day on the job. The 87-year-old is now officially retired. He took time out from serving cupcakes for a couple of photos, but after that in true Malcolm Pearce form it was right back to work. Pearce started ...
Apr. 10—It wasn't a thing of beauty, but second-year Centennial coach Richard Starrett is happy just the same. The Golden Hawks shook off a shaky offensive performance and overcame three turnovers and nearly 100 yards in penalties to hold off visiting Stockdale 20-14 on Friday night at Centennial. "I'll take a win by one point or one million at this point," Starrett said. "So it feels good to ...
Apr. 10—OXFORD — There are stars in front of him, stars behind and even stars off to the side. Kinkead Dent isn't looking at stars, never has. Ole Miss starting quarterback Matt Corral, a four-star recruit, is getting some Heisman Trophy mention. But if Corral should be forced to miss an extended period of time next fall, the keys to one of the country's most explosive offenses could go to Dent ...
Dodge is setting horsepower and speed records, but there’s a nefarious side to the brand’s record setting attention.
NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”), of the important May 3, 2021 lead plaintiff deadline. SO WHAT: If you purchased Athenex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Athenex class action, go to http://www.rosenlegal.com/cases-register-2051.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 3, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the data included in the Oral Paclitaxel and Encequidar New Drug Application (“NDA”) presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (2) the uncertainty over the results of the primary endpoint of objective response rate (“ORR”) at week 19 conducted by blinded independent central review (“BICR”); (3) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (4) Athenex’s Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (5) as a result, it was foreseeable that the FDA would not approve Athenex’s NDA in its current form; and (6) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Athenex class action, go to http://www.rosenlegal.com/cases-register-2051.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 firstname.lastname@example.org email@example.com firstname.lastname@example.org www.rosenlegal.com
Kim Kardashian shares children North, Saint, Chicago and Psalm with estranged husband Kanye West
Justin Rose stretched his lead to three strokes early in Saturday's third round of the Masters with three-time major winner Jordan Spieth on his heels and Canada's Corey Conners leaping into contention with an ace.
The Valkyries scored 10 unanswered on way to state semifinals victory.
The Rock backed President Biden in last year’s smackdown of an election, but Dwayne Johnson may have caught the White House bug himself to one day succeed Uncle Joe. Always savvy on social media, the Fast & Furious franchise star went online this morning to weigh in on a recent Newsweek poll that found almost […]
(This article contains some light spoilers for the new Amazon horror series “Them”) Amazon’s “Them,” from creator Little Marvin, tells the story of a Black family from North Carolina who moves to Los Angeles in 1953 after they suffer an unimaginable tragedy. The Emorys have family out there, and they’re hoping things will be better for them out there in Southern California. Unfortunately, troubles arises when they move into what was otherwise an all-white neighborhood — and the white folks who live there are extremely unhappy about having Black neighbors. And so they do a lot of bad stuff to the Emorys, who also have some other literal demons to deal with since this is a horror show. The Emorys that we see on “Them” are not real people, and this is not a true story. But it is firmly rooted in actual history. “Them” puts a horror lens on stuff like racist covenants, predatory lending, redlining — it is, in a lot of ways, a big picture examination of the shape of institutional racism in America in the 20th Century. It’s got a focus on housing in particular, but it’s certainly not limited to that topic. Also Read: 'For All Mankind': Margot Really Needs to Stop Talking to Aleida Like That As we see at the very beginning of the first episode, the Emorys’ move across the country was part of a major trend in the mid-20th Century, when millions of Black families moved out of the South and into other parts of the country. But while things may have been overall better in general in California, that doesn’t mean there wasn’t still plenty of racism to go around out there. The beginning of the fifth episode, dubbed “COVENANT I,” gives you a partial overview of the racist mid-20th Century housing situation. In this scene, a bunch of bankers discuss the way they use dramatically unfair policies to create neighborhoods full of Black people who are paying outrageous interest rates on their homes. Interest rates that are much, much higher than what the white people have to pay. The country was still a long way away from the Fair Housing Act of 1968 — though that hardly put an end to racist housing discrimination. This scene is just part of the story. The Federal Housing Administration in the first half of the 20th Century enacted overtly racist policies with the specific goal of segregating neighborhoods and keep people of color out of white neighborhoods. Though they tried to use what they presumably thought was well-meaning language — “incompatible racial groups should not be permitted to live in the same communities” — it’s not difficult at all to see what they were doing. Also Read: Incel Captain America Is So Perfect In the scene I mentioned above, we see maps of Los Angeles with the neighborhoods assigned a color based on “residential security.” Areas in red are “hazardous” — and red areas, not at all coincidentally, also represent Black neighborhoods. This is something called “redlining,” and it had a larger tangible effect than just what we see here. That’s because that map doesn’t belong to the banks represented in this scene. It was an official government map. And the FHA would not insure mortgages for homes in the areas shaded in red. Which, in essence and function, meant Black people had (and still have) a much harder time getting mortgages than white people, and when they were able to, they paid much higher interest rates to offset the increased risk of uninsured loans. Without insurance on the loan, the bank would issue a predatory mortgage with interest so high that the standard monthly payments won’t even cover the interest, locking them into a lifetime of debt because they’ll never be able to afford to actually pay down the loan at all unless they start making a whole lot more money. Which isn’t too likely given all the other ways American racism manifests. And then on top of all that, the banks themselves were racist and just generally favored white people, and were happy to exploit Black folks. The story of the Emorys on “Them” appears to actually be something a little bit different, and an example of another racist trick the banks used to pull. When Lucky (Deborah Ayorinde) goes to the bank to try to get the ball rolling on selling the house because the neighbors are so racist, the woman there tells her it isn’t possible. “It’s not a lease in the technical sense. There’s no bank mortgage, and the debt is amortized without any accrual of equity,” she tells Lucky. What the Emorys bought is a contract. The bank buys the house from another bank, keeps the deed, and then basically rents it out under awful, unforgiving terms with the promise that the family will only own it once the debt is paid in full. Which, as mentioned above, probably won’t ever happen because the terms are structured to prevent them from ever being able to. And also the Emorys don’t get any of the wealth accrual benefits of owning a home, because they don’t actually own it. This is basically a rent-to-own scheme, but much worse. Also Read: So Who Actually Won in 'Godzilla vs Kong'? On top of that, we have the covenant. In the Emorys’ agreement with the bank, there’s a pretty weird provision: “No lot in said tract shall be sold, rented or leased to any persons whose blood is not entirely that of the Caucasian race. No persons of Negro blood or heritage shall occupy the premises, notwithstanding domestic servants actually employed by a person of the Caucasian race.” These racist covenants were also a thing, and they were made illegal in 1948 in the court case Shelley v. Kraemer when the Supreme Court declared such nonsense as violations of the 14th Amendment, which claims to guarantee equal protection under the law. So the woman from the bank isn’t just messing with the Emorys when she says those covenants aren’t enforceable. And, yes, Compton had some of these covenants in place back in the day. In the present, Compton is quite ethnically diverse. But, as it is on “Them,” it wasn’t always the case. In the early days of the 20th Century the town was actually an enclave of Japanese-American folks — but the government put them all in concentration camps during World War II, leaving the neighborhood mostly white. The demographics began to change in the 1950s. To the north of Compton is Watts, already a predominantly Black neighborhood in the early 1950s. As the Black population of Los Angeles grew, some families moved into nearby West Compton. East Compton was much slower to change, and it stayed mostly white for a couple more decades. So while “Them” is not “based on a true story” in the traditional sense, it is definitely has its basis on many, many real things that many Black people have in the past experienced and still experience to this day. Creator Little Marvin and co. crafted an original horror tale, but it’s a tale rooted in real suffering. Read original story Is the Amazon Series ‘Them’ Based on a True Story? At TheWrap
USC exploded for 11 runs from the fifth inning on Saturday.
After searching an inmate, the deputies began experiencing symptoms because of the powerful opioid.
Argentine Economy Minister Martin Guzman will travel to Europe on Sunday to build support among G7 and G40 nations for a renegotiation of its multibillion-dollar debts to the International Monetary Fund (IMF) and the Paris Club group of creditor nations. Guzman will travel to Germany, France, Italy and Spain, where he will meet his counterparts and other officials to outline Argentina's restructuring plans during a five-day trip. "The objective is to get the necessary support from IMF shareholders (especially G7 and G20) to finalize a program that will serve Argentina," the Ministry of Economy said in a statement.
One stoppage-time goal slowed Manchester City's march to the Premier League title. Another ignited Liverpool's push for the Champions League qualification positions. A day of dramatic finishes in England's top flight began with City losing 2-1 to 10-man Leeds, whose winning goal — scored by Stuart Dallas for his second of the match — came from a breakaway in the first minute of added-on time at Etihad Stadium.
BALTIMORE — Maryland topped 1,500 new coronavirus cases again on Saturday, continuing to push its 2-week average in the wrong direction, Maryland health officials reported. The state reported 1,584 new cases, the second day in a row the number topped 1,500. Over the last two weeks, Maryland has averaged 1,324 new infections daily, the highest 14-day average since Feb. 11. The increase came ...
Nikki Grahame, a reality TV star best known for her apperance in the seventh season of Big Brother UK, has died aged 38. “Nikki Grahame passed away in the early hours of Friday 9th April 2021,” said a statement from her representative. “Please respect the privacy of Nikki’s friends and family at this tragic and […]